8-K: Invivyd Secures FDA IND Clearance for VYD2311 COVID Antibody

Invivyd, Inc. announced U.S. FDA Investigational New Drug (IND) clearance and alignment on the pivotal clinical program for VYD2311, a vaccine-alternative antibody to prevent COVID.

Summary

• The U.S. FDA has cleared the Investigational New Drug (IND) application for VYD2311, Invivyd's vaccine-alternative monoclonal antibody candidate for COVID prevention.
• The FDA provided feedback to advance the REVOLUTION clinical program, which includes two pivotal clinical trials: DECLARATION and LIBERTY.
• The DECLARATION Phase 3 trial will evaluate the safety and prevention of symptomatic COVID at three months from a single intramuscular (IM) dose of VYD2311, with a second arm assessing monthly IM doses. Total expected enrollment is approximately 2,000 people.
• The LIBERTY trial will assess the safety and tolerability of VYD2311 against mRNA-based COVID vaccines and explore co-administration. Total expected enrollment is approximately 300 people.
• Both DECLARATION and LIBERTY clinical trials are expected to begin around year-end 2025, with top-line data anticipated mid-2026.
• Commercial launch quantities of VYD2311 have been produced and are ready.
• The clinical trials are funded by Invivyd's recent capital raise.
• Further details on the REVOLUTION clinical program will be shared in a public investor event later this month.

Sentiment

Score: 8

Explanation: The IND clearance and FDA alignment for a pivotal Phase 3 program are significant positive milestones for a biopharmaceutical company, indicating strong progress towards potential market entry for a new COVID prevention option. The readiness of commercial quantities and secured funding further de-risk the immediate future.

Positives

• U.S. FDA Investigational New Drug (IND) application for VYD2311 has been cleared, enabling the initiation of pivotal clinical trials.
• Alignment has been achieved with the U.S. FDA on the design of the pivotal DECLARATION and LIBERTY clinical programs.
• The DECLARATION Phase 3 trial is designed to evaluate both single and monthly intramuscular doses, offering potential flexibility and individual choice for COVID protection.
• The LIBERTY trial will provide comparative safety and tolerability data against mRNA-based COVID vaccines and explore co-administration.
• Commercial launch quantities of VYD2311 are already produced and available.
• Invivyd has secured capital from a recent raise to fund clinical trial execution through pivotal data readouts, de-risking the immediate development pathway.
• VYD2311 is engineered to offer a patient-friendly intramuscular route of administration and optimized for neutralizing contemporary virus lineages.

Risks

• The timing, progress, and results of discovery, preclinical, and clinical development activities, including finalization and initiation of the DECLARATION and LIBERTY clinical trials, are uncertain.
• Clinical trial site activation or enrollment rates may vary and impact timelines.
• Results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis.
• Unexpected safety or efficacy data could be observed during preclinical studies or clinical trials.
• The predictability of clinical success based on neutralizing activity in nonclinical studies is not guaranteed.
• Potential variability in neutralizing activity of product candidates tested in different assays (e.g., pseudovirus vs. authentic assays) exists.
• Variability of results in models and methods used to predict activity against SARS-CoV-2 variants is a factor.
• There is a risk that the epitopes targeted by VYD2311 and pemivibart may not remain structurally intact.
• Product candidates may not be able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly with viral evolution.
• Changes in the regulatory environment and the outcome of engagement with regulators could affect development.
• Uncertainties related to the regulatory approval process and available development and regulatory pathways exist.
• The company's ability to generate the data needed to support a potential Biologics License Application (BLA) submission for VYD2311 is critical.
• The duration and potential revision or revocation of the Emergency Use Authorization (EUA) granted by the FDA for another mAb in the company's pipeline are uncertain.
• Maintaining an acceptable safety, tolerability, and efficacy profile of any product candidate following regulatory authorization or approval is essential.
• Changes in expected or existing competition could impact market potential.
• Reliance on third parties for various aspects of development and manufacturing poses risks.
• Complexities of manufacturing mAb therapies and the future availability of commercial launch product quantities are challenges.
• Macroeconomic and political uncertainties could affect operations.
• The company's ability to continue as a going concern and whether it has adequate funding to meet future operating expenses and capital expenditure requirements are ongoing considerations.

Future Outlook

Invivyd expects to initiate the DECLARATION and LIBERTY clinical trials around year-end 2025, with top-line data anticipated mid-2026. The company aims to provide Americans with a new choice for COVID protection, offering a convenient, safe, high-quality option without repeated use of inflammatory COVID vaccines. Post-approval, additional studies in the REVOLUTION program, including pediatric and Phase 4 studies, may be conducted to further establish VYD2311 and potential future Invivyd antibodies as the preferred option for COVID prevention over mRNA-based vaccination.

Management Comments

• "We are moving as fast as possible to bring Americans a new choice in protection from COVID." Marc Elia, Chairman of Invivyd's Board of Directors.
• "We have designed the DECLARATION and LIBERTY clinical trials towards providing Americans with a convenient, safe, high-quality protective option to avoid COVID harm and burden without repeated use of inflammatory COVID vaccines." Marc Elia.
• "These trials and the broader REVOLUTION program will aim to generate clinical data that support a new approach to COVID prevention: one that enables at-risk Americans to exercise their individual freedom of choice to select the timing and quantity of safe, high quality protection both annually and during periods of heightened risk such as medical vulnerability or major COVID waves, as well as during life's important moments, such as family gatherings, holidays, and travel." Marc Elia.
• "COVID antibody medicines build on the science of natural, human immunity that begins at birth with maternal antibody transfer, and could serve as a critical, first-line option for protection for millions of Americans." Marc Elia.

Industry Context

This announcement positions VYD2311 as a significant entrant in the COVID-19 prevention market, specifically targeting individuals seeking a vaccine-alternative monoclonal antibody. Invivyd emphasizes the potential for VYD2311 to offer individual choice, flexibility in dosing, and a potentially superior safety and tolerability profile compared to existing mRNA-based COVID vaccines. This strategy aims to capture a segment of the population that may be hesitant about or medically unsuited for traditional vaccination, thereby expanding the overall market for COVID protection options.

Comparison to Industry Standards

• VYD2311 is being developed as a novel monoclonal antibody (mAb) candidate for COVID-19 prevention, offering an alternative to existing mRNA-based COVID vaccines.
• The LIBERTY clinical trial is specifically designed to conduct a head-to-head comparison of VYD2311's safety and tolerability against mRNA-based COVID vaccines.
• Invivyd aims to establish VYD2311 as a preferred option for COVID protection over mRNA-based vaccination, suggesting a competitive advantage in terms of patient choice, administration flexibility, and potentially a more favorable safety profile.
• VYD2311 leverages the same antibody backbone as pemivibart, Invivyd's investigational mAb granted emergency use authorization (EUA) for pre-exposure prophylaxis (PrEP) of COVID-19, and adintrevimab, another investigational mAb with robust safety data from global Phase 2/3 clinical trials.

Stakeholder Impact

• **Shareholders**: Positive impact due to significant progress in the clinical development pipeline, potential for future revenue from VYD2311, and de-risking through IND clearance and secured funding.
• **Patients/Public at risk for COVID**: Potential benefit from a new, alternative prophylactic option for COVID-19, especially those seeking non-vaccine protection or with specific medical needs.
• **Employees**: Continued employment and potential growth opportunities as the company advances its clinical programs.
• **Regulators (FDA)**: Successful collaboration and alignment on clinical trial design.

Next Steps

• Initiate the DECLARATION and LIBERTY clinical trials around year-end 2025.
• Share more details about the REVOLUTION clinical program for VYD2311 in a public investor event later this month.
• Anticipate top-line data from the DECLARATION and LIBERTY clinical trials mid-2026.
• Potentially conduct pediatric and other post-approval Phase 4 studies within the REVOLUTION program if a Biologics License Application (BLA) is granted by the FDA.
• Pursue a Biologics License Application (BLA) for VYD2311 following successful clinical trial completion.

Key Dates

Recommendation

The U.S. FDA's Investigational New Drug (IND) clearance and alignment on the pivotal Phase 3 clinical program for VYD2311 represent a major de-risking event and a significant step towards commercialization. The company has secured funding for these trials and has commercial quantities ready, indicating strong operational readiness. VYD2311 targets a large and ongoing market need for COVID prevention, particularly as a vaccine alternative, which could capture a substantial market share. The clear timeline for trial initiation and top-line data provides visibility for investors. This progress significantly enhances the company's valuation prospects.

Keywords

Invivyd, IVVD, VYD2311, COVID-19, Monoclonal Antibody, IND Clearance, FDA, Clinical Trials, DECLARATION, LIBERTY, Vaccine Alternative, Biopharmaceutical, SARS-CoV-2, Prophylaxis, REVOLUTION program